BET À DAY
A committee of American experts ruled on Tuesday in favor of a vaccine recall specifically targeting Omicron, auguring a need for annual injections against COVID-19, like the flu.
The scientists, invited by the American drug agency, the FDA, approved the measure by 19 votes to 2 after a day spent reviewing the available data, including projections for future waves and preliminary results provided by vaccine manufacturers.
An FDA scientist summed up the complexity of the situation: anticipating the evolution of a virus that has often defied predictions and mutates even faster than the flu.
“We are working in a very complicated area today, because none of us have a crystal ball,” he said.
A member of the committee, Professor of Medicine Michael Nelson of the University of Virginia said he voted in favor of the measure, because he feared that the declining effectiveness of vaccines could translate into serious cases for people at high risk. “We must take action without delay.”
Pfizer and Moderna, which recently announced that their vaccines developed specifically against the Omicron variant were showing promising results, addressed the expert committee on Tuesday, as did Novavax.
Experts did not have to specify which sub-variant of Omicron they would like to see targeted: BA.1, the initial version, or BA.4 and BA.5, which are spreading rapidly throughout the world.
But during from their discussions, most scientists seemed to favor a vaccine that would target both the first strain of the virus, to achieve broad protection, and the later BA.4 and BA.5 subvariants.
< p>Pfizer and Moderna reported being able to move into production of such vaccines within three months.
Unlike the Alpha and Delta variants, which eventually faltered, Omicron and its subvariants have dominated the contaminations during the year 2022, so much so that they now represent the vast majority of infections from around the world, FDA's Jerry Weir told the committee.
This trend makes it more likely that the COVID-19 virus will evolve within the Omicron business in the future.